ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0522

Rates of Clinical Events in Patients with CKD: A UK Population-Based Cohort Study

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Abdul Sultan, Alyshah, AstraZeneca, Cambridge, United Kingdom
  • Sun, Ping, AstraZeneca, Cambridge, United Kingdom
  • Hedman, Katarina, AstraZeneca, Gothenburg, Sweden
  • Wang, Xia, AstraZeneca, Gaithersburg, Maryland, United States
  • Houser, Mark T., AstraZeneca, Gaithersburg, Maryland, United States
  • Little, Dustin J., AstraZeneca, Gaithersburg, Maryland, United States
  • James, Glen, AstraZeneca, Cambridge, United Kingdom
Background

Epidemiology of clinical event rates in patients with chronic kidney disease (CKD) is limited and can impede the ability of dialysis organizations, government agencies, other institutions, and payers to counsel patients and assess quality of care.

Methods

The Clinical Practice Research Datalink (CPRD) is a large, longitudinal UK-based primary care database that covers 6% (~4 million people) of the population. CPRD is linked to Hospital Episode Statistics (HES), which contains information on all hospital admissions in England. We identified CKD patients with eGFR <60 ml/min/1.73m2 in CPRD between 2004 and 2017. Adverse clinical events were identified using ICD-10 and READ codes. Non-dialysis dependent (NDD) patients were staged by eGFR. Dialysis dependent (DD) patients were identified using Classification of Interventions and Procedures (OPCS) and READ codes. Clinical events were identified by ICD10 and READ codes. Incidence rates per 100 person-years (PY) were calculated for selected adverse event stratified by dialysis status and CKD stage.

Results

We identified 310362 NDD and 5248 DD patients with a mean (standard deviation [SD]) age of 75.5 (10.2) years and a median (interquartile range [IQR]) follow-up of 87.5 (46.5-130.9) months. Among NDD patients 96%, 3%, and 1% of patient-years came from CKD 3, 4, and 5, respectively. Most event rates were consistently higher in DD CKD patients, compared to NDD CKD patients; and higher among CKD 4/5 compared to CKD 3 patients (Table 1).

Conclusion

Our results help establish baseline rates of specific clinical events and provide additional evidence of increased morbidity for DD vs. NDD patients, and for NDD patients with more severe vs. less severe kidney disease.

Funding

  • Commercial Support